drugset
drugset / Trial / NCT05117957

Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study

NCT05117957 ↗

Phase 2 Completed 50 enrolled Bo Hyun Kim
NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy and safety of sorafenib administered as later lines of treatment in patients with advanced HCC.

Timeline

Start
2022-03-08
Primary completion
2025-06-30
Completion
2025-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 600 mg Oral

Indications

hepatocellular carcinoma